biostudies-literatureUnknownFlack JMNational Institute for Health Research (NIHR)AstraZeneca<h4>Background</h4>Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood pressure of patients with uncontrolled or resistant hypertension.<h4>Methods</h4>In this phase 3, multinational, double-blind, randomized, placebo-controlled trial, we recruited patients with a seated systolic blood pressure of between 140 mm Hg and less than 170 mm Hg despite the receipt of stable treatment with two antihypertensive medications (uncontrolled hypertension) or three or more such medications (resistant hypertension), including a diuretic. After a 2-week placebo run-in period, we randomly assigned patients with a seated systolic blood pressure of 135 mm Hg or more iThe New England journal of medicinehttps://www.ebi.ac.uk/biostudies/studies/S-EPMC7618089biostudies-literatureEfficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.PMC7618089uclbrc-2012-1UCLBRC-2012-1Dwyer JPFronczek JOlsson DSAzizi MShibata HPerl SWilderang UWilliams BBaxHTN InvestigatorsBrown JMWittes JJones ESWWang JGFlack JMfalseEfficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.<h4>Background</h4>Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood pressure of patients with uncontrolled or resistant hypertension.<h4>Methods</h4>In this phase 3, multinational, double-blind, randomized, placebo-controlled trial, we recruited patients with a seated systolic blood pressure of between 140 mm Hg and less than 170 mm Hg despite the receipt of stable treatment with two antihypertensive medications (uncontrolled hypertension) or three or more such medications (resistant hypertension), including a diuretic. After a 2-week placebo run-in period, we randomly assigned patients with a seated systolic blood pressure of 135 mm Hg or more i2025-01-01T00:00:00Z2025 Aug2026-06-02T20:25:47.8Z2026-04-20T03:10:06.805ZS-EPMC76180894088873010.1056/NEJMoa2507109